Platinum-containing regimens for metastatic breast cancer.
CONCLUSIONS: In women with metastatic breast cancer who do not have triple-negative disease, there is high-quality evidence of little or no survival benefit and excess toxicity from platinum-based regimens. There is preliminary low-quality evidence of a moderate survival benefit from platinum-based regimens for women with mTNBC. Further randomised trials of platinum-based regimens in this subpopulation of women with metastatic breast cancer are required.
PMID: 28643430 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N Tags: Cochrane Database Syst Rev Source Type: research
More News: Alopecia | Anemia | Borderline Tumor | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Databases & Libraries | General Medicine | International Medicine & Public Health | Statistics | Study | Toxicology | WHO | Women